Literature DB >> 20061792

Molecular vaccines for malaria.

Joseph T Bruder1, Evelina Angov, Keith J Limbach, Thomas L Richie.   

Abstract

The basic premise of vaccination is the triggering of host immune responses leading to the induction of adaptive immunity having sufficient magnitude and duration to provide long term protection. This has been achieved by many licensed vaccines, the majority based on attenuated or inactivated organisms, although often the protective antigens and underlying molecular mechanisms have not been identified. However, this traditional approach has not led to the development of a licensed vaccine for malaria or for several other devastating infectious diseases. Recently, substantial efforts have been focused on applying rational molecular design principles toward the development of novel vaccines for these refractory pathogens. In this review, we discuss the molecular aspects of antigen design, adjuvant advancement and the development of vaccine delivery systems as they are being applied to malaria vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20061792     DOI: 10.4161/hv.6.1.10463

Source DB:  PubMed          Journal:  Hum Vaccin        ISSN: 1554-8600


  8 in total

1.  Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites.

Authors:  Sebastian A Mikolajczak; John B Sacci; Patricia De La Vega; Nelly Camargo; Kelly VanBuskirk; Urszula Krzych; Jun Cao; Marcelo Jacobs-Lorena; Alan F Cowman; Stefan H I Kappe
Journal:  Cell Microbiol       Date:  2011-06-24       Impact factor: 3.715

Review 2.  Plasmodium immunomics.

Authors:  Denise L Doolan
Journal:  Int J Parasitol       Date:  2010-09-16       Impact factor: 3.981

3.  Immunization with apical membrane antigen 1 confers sterile infection-blocking immunity against Plasmodium sporozoite challenge in a rodent model.

Authors:  Sophie Schussek; Angela Trieu; Simon H Apte; John Sidney; Alessandro Sette; Denise L Doolan
Journal:  Infect Immun       Date:  2013-07-08       Impact factor: 3.441

4.  Alga-produced malaria transmission-blocking vaccine candidate Pfs25 formulated with a human use-compatible potent adjuvant induces high-affinity antibodies that block Plasmodium falciparum infection of mosquitoes.

Authors:  Kailash P Patra; Fengwu Li; Darrick Carter; James A Gregory; Sheyenne Baga; Steven G Reed; Stephen P Mayfield; Joseph M Vinetz
Journal:  Infect Immun       Date:  2015-02-17       Impact factor: 3.441

5.  Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.

Authors:  Martha Sedegah; Yohan Kim; Bjoern Peters; Shannon McGrath; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna Banania; Maria Belmonte; Renato Sayo; Fouzia Farooq; Denise L Doolan; David Regis; Cindy Tamminga; Ilin Chuang; Joseph T Bruder; C Richter King; Christian F Ockenhouse; Bart Faber; Edmond Remarque; Michael R Hollingdale; Thomas L Richie; Alessandro Sette
Journal:  Malar J       Date:  2010-08-24       Impact factor: 2.979

Review 6.  Vaccines against malaria.

Authors:  Adrian V S Hill
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2011-10-12       Impact factor: 6.237

7.  Adenovirus 5-vectored P. falciparum vaccine expressing CSP and AMA1. Part A: safety and immunogenicity in seronegative adults.

Authors:  Martha Sedegah; Cindy Tamminga; Shannon McGrath; Brent House; Harini Ganeshan; Jennylynn Lejano; Esteban Abot; Glenna J Banania; Renato Sayo; Fouzia Farooq; Maria Belmonte; Nalini Manohar; Nancy O Richie; Chloe Wood; Carole A Long; David Regis; Francis T Williams; Meng Shi; Ilin Chuang; Michele Spring; Judith E Epstein; Jose Mendoza-Silveiras; Keith Limbach; Noelle B Patterson; Joseph T Bruder; Denise L Doolan; C Richter King; Lorraine Soisson; Carter Diggs; Daniel Carucci; Sheetij Dutta; Michael R Hollingdale; Christian F Ockenhouse; Thomas L Richie
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

Review 8.  The case for a rational genome-based vaccine against malaria.

Authors:  Carla Proietti; Denise L Doolan
Journal:  Front Microbiol       Date:  2015-01-22       Impact factor: 5.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.